Nexalin Q1 FY26 net loss widens 5% to $2.1 million; revenue drops 64% to $14,950

Nexalin Technology, Inc.

Nexalin Technology, Inc.

NXL

0.00

  • Nexalin Technology reported a net loss of USD 2.1 million for the three months ended March 31, 2026, widening 5%.
  • Revenue fell 64% to USD 14,950.
  • Operating loss widened 5% to USD 2.12 million as operating expenses rose 5% to USD 2.13 million.
  • Professional fees climbed 35% to USD 495,296, while salaries and benefits increased 49% to USD 498,560.
  • Entered a Scope of Work with Lindus Health for a pivotal HALO Clarity insomnia clinical trial, with direct fees of about USD 944,820 plus pass-through expenses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-004854), on May 08, 2026, and is solely responsible for the information contained therein.